Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

Inclusion Criteria:

1. Subject is male or female > 18 years of age.
2. Subject has an untreated primary malignancy of breast, lung, colorectal, prostate,bladder, uterine, kidney/renal pelvis, pancreatic, liver, stomach, ovarian oresophageal cancer. OR Subject has suspicion of a primary malignancy of pancreatic, bladder, kidney/renalpelvis, or ovarian cancer based on imaging.
3. Subject understands the study procedures and is able to provide informed consent toparticipate in the study and authorization for release of relevant protected healthinformation to the study Investigator.

Exclusion Criteria:

1. Prior or concurrent cancer diagnosis defined as:
2. Any previous cancer diagnosis within the past 5 years (with the exceptions ofbasal cell or squamous cell skin cancers); OR
3. Recurrence of the same primary cancer within any timeframe; OR
4. Concurrent diagnosis of multiple primary cancers
5. Chemotherapy and/or radiation therapy within 5 years prior to enrollment/samplecollection.
6. Any treatment for the primary malignancy or sites of metastases. Subject may not havestarted neo-adjuvant chemotherapy, neo-adjuvant radiation therapy, immunotherapy orother treatment and/or surgery prior to blood sample collection.
7. Less than 3 days between fine needle aspiration (FNA) of target pathology and bloodcollection.
8. Less than 7 days between biopsy (other than FNA) of target pathology and bloodcollection.
9. IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.
10. Individual has a condition the Investigator believes would interfere with his or herability to provide informed consent, comply with the study protocol, which mightconfound the interpretation of the study results or put the person at undue risk.